{"id":22796,"date":"2024-03-28T17:59:20","date_gmt":"2024-03-28T16:59:20","guid":{"rendered":"https:\/\/mabdesign.fr\/osivax-announces-vaccination-of-last-patient-in-phase-2a-clinical-trial-evaluating-ovx836-combined-with-qivs\/"},"modified":"2024-03-28T17:59:20","modified_gmt":"2024-03-28T16:59:20","slug":"osivax-announces-vaccination-of-last-patient-in-phase-2a-clinical-trial-evaluating-ovx836-combined-with-qivs","status":"publish","type":"post","link":"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-last-patient-in-phase-2a-clinical-trial-evaluating-ovx836-combined-with-qivs\/","title":{"rendered":"Osivax Announces Vaccination of Last Patient in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs"},"content":{"rendered":"\n<p>Lyon, France\u00a0<strong>\u2013 March 26, 2024\u00a0\u2013<\/strong> <a href=\"https:\/\/osivax.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">Osivax<\/a>,\u00a0a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced\u00a0that all participants have completed their final visit in the Phase 2a clinical trial (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05734040\" target=\"_blank\" rel=\"noreferrer noopener\">NCT05734040<\/a>) evaluating OVX836, Osivax\u2019 broad-spectrum influenza A vaccine candidate, in combination with Quadrivalent Influenza Vaccines (QIVs). Topline results from this study are expected in the second half of 2024.<\/p>\n\n\n\n<p>The randomized, double-blind, double placebo-controlled, parallel-group, multicentric clinical trial evaluated the safety and immunogenicity of a 480\u03bcg dose of the OVX836 vaccine with licensed QIVs and placebo in healthy participants across Australia. The enrolled 478 healthy volunteers from 18 to 60 years old were observed over a period of 180 days following the concomitant administration of the OVX836 vaccine with licensed QIVs, as two separate intramuscular injections into opposite arms, compared to one administration of OVX836, QIVs or placebo.&nbsp;<\/p>\n\n\n\n<p>Laboratory analyses of the vaccine immunogenicity are being performed at VisMederi \u2013 Siena, KCAS Bio \u2013 Lyon, Osivax Quality Control lab \u2013 Angleur, and the CEVAC lab \u2013 Ghent.<\/p>\n\n\n\n<p>\u201c<em>The data gathered from this Phase 2a trial is a necessary step in demonstrating OVX836\u2019s ability to provide long-lasting, improved protection in combination with QIVs. We look forward to analyzing the data to confirm the promising results we have observed with OVX836 to date,\u201d&nbsp;<\/em>commented&nbsp;<strong>Dr. Nicola Groth, CMO of Osivax<\/strong><strong>.&nbsp;<\/strong><em>\u201c<\/em><em>We would like to thank the volunteers and dedicated staff of researchers and clinicians whose contributions have ensured the trial\u2019s successful completion.<\/em>\u201d<\/p>\n\n\n\n<p>\u201c<em>The need for more effective and safe flu vaccines remains high and the conclusion of our trial which evaluates OVX836 in combination with QIVs brings us one step closer to providing improved protection,<\/em>\u201d said\u00a0<strong>Alexandre Le Vert, CEO and Co-Founder of Osivax<\/strong>.\u00a0\u201c<em>The data collected from this trial will bolster our development of OVX836 as a broad-spectrum influenza vaccine.\u201d\u00a0<\/em> <a href=\"https:\/\/osivax.com\/lplv-ovx836-006-pr\/\">To know more<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Osivax,\u00a0a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced\u00a0that all participants have completed their final visit in the Phase 2a clinical trial (NCT05734040) evaluating OVX836, Osivax\u2019 broad-spectrum influenza A vaccine candidate, in combination with Quadrivalent Influenza Vaccines (QIVs).<\/p>\n","protected":false},"author":3,"featured_media":7695,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36,32],"tags":[],"class_list":["post-22796","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-our-members"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Osivax Announces Vaccination of Last Patient in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs - MabDesign<\/title>\n<meta name=\"description\" content=\"Osivax,\u00a0a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced\u00a0that all participants have completed their final visit in the Phase 2a clinical trial (NCT05734040) evaluating OVX836, Osivax\u2019 broad-spectrum influenza A vaccine candidate, in combination with Quadrivalent Influenza Vaccines (QIVs).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-last-patient-in-phase-2a-clinical-trial-evaluating-ovx836-combined-with-qivs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Osivax Announces Vaccination of Last Patient in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs - MabDesign\" \/>\n<meta property=\"og:description\" content=\"Osivax,\u00a0a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced\u00a0that all participants have completed their final visit in the Phase 2a clinical trial (NCT05734040) evaluating OVX836, Osivax\u2019 broad-spectrum influenza A vaccine candidate, in combination with Quadrivalent Influenza Vaccines (QIVs).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-last-patient-in-phase-2a-clinical-trial-evaluating-ovx836-combined-with-qivs\/\" \/>\n<meta property=\"og:site_name\" content=\"MabDesign\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-28T16:59:20+00:00\" \/>\n<meta name=\"author\" content=\"Laure Delhon\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:site\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Laure Delhon\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-last-patient-in-phase-2a-clinical-trial-evaluating-ovx836-combined-with-qivs\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-last-patient-in-phase-2a-clinical-trial-evaluating-ovx836-combined-with-qivs\/\"},\"author\":{\"name\":\"Laure Delhon\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/e7f929f9c28647aff12061d31ac44f39\"},\"headline\":\"Osivax Announces Vaccination of Last Patient in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs\",\"datePublished\":\"2024-03-28T16:59:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-last-patient-in-phase-2a-clinical-trial-evaluating-ovx836-combined-with-qivs\/\"},\"wordCount\":319,\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-last-patient-in-phase-2a-clinical-trial-evaluating-ovx836-combined-with-qivs\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/09\/OSIVAX-logo.jpg\",\"articleSection\":[\"News\",\"Our members\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-last-patient-in-phase-2a-clinical-trial-evaluating-ovx836-combined-with-qivs\/\",\"url\":\"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-last-patient-in-phase-2a-clinical-trial-evaluating-ovx836-combined-with-qivs\/\",\"name\":\"Osivax Announces Vaccination of Last Patient in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs - MabDesign\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-last-patient-in-phase-2a-clinical-trial-evaluating-ovx836-combined-with-qivs\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-last-patient-in-phase-2a-clinical-trial-evaluating-ovx836-combined-with-qivs\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/09\/OSIVAX-logo.jpg\",\"datePublished\":\"2024-03-28T16:59:20+00:00\",\"description\":\"Osivax,\u00a0a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced\u00a0that all participants have completed their final visit in the Phase 2a clinical trial (NCT05734040) evaluating OVX836, Osivax\u2019 broad-spectrum influenza A vaccine candidate, in combination with Quadrivalent Influenza Vaccines (QIVs).\",\"breadcrumb\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-last-patient-in-phase-2a-clinical-trial-evaluating-ovx836-combined-with-qivs\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-last-patient-in-phase-2a-clinical-trial-evaluating-ovx836-combined-with-qivs\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-last-patient-in-phase-2a-clinical-trial-evaluating-ovx836-combined-with-qivs\/#primaryimage\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/09\/OSIVAX-logo.jpg\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/09\/OSIVAX-logo.jpg\",\"width\":600,\"height\":152},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-last-patient-in-phase-2a-clinical-trial-evaluating-ovx836-combined-with-qivs\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/mabdesign.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Osivax Announces Vaccination of Last Patient in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"name\":\"Mabdesign\",\"description\":\"The Biotherapy Expert\",\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mabdesign.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\",\"name\":\"Mabdesign\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"width\":786,\"height\":233,\"caption\":\"Mabdesign\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/MabDesign_fr\",\"https:\/\/www.linkedin.com\/company\/mabdesign\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/e7f929f9c28647aff12061d31ac44f39\",\"name\":\"Laure Delhon\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/066cd19881c24784247d7cba92fef00a9cef88209b15a463ee495ac0fc2ba664?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/066cd19881c24784247d7cba92fef00a9cef88209b15a463ee495ac0fc2ba664?s=96&d=mm&r=g\",\"caption\":\"Laure Delhon\"},\"url\":\"https:\/\/mabdesign.fr\/en\/author\/laure-delhonmabdesign-fr\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Osivax Announces Vaccination of Last Patient in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs - MabDesign","description":"Osivax,\u00a0a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced\u00a0that all participants have completed their final visit in the Phase 2a clinical trial (NCT05734040) evaluating OVX836, Osivax\u2019 broad-spectrum influenza A vaccine candidate, in combination with Quadrivalent Influenza Vaccines (QIVs).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-last-patient-in-phase-2a-clinical-trial-evaluating-ovx836-combined-with-qivs\/","og_locale":"en_US","og_type":"article","og_title":"Osivax Announces Vaccination of Last Patient in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs - MabDesign","og_description":"Osivax,\u00a0a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced\u00a0that all participants have completed their final visit in the Phase 2a clinical trial (NCT05734040) evaluating OVX836, Osivax\u2019 broad-spectrum influenza A vaccine candidate, in combination with Quadrivalent Influenza Vaccines (QIVs).","og_url":"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-last-patient-in-phase-2a-clinical-trial-evaluating-ovx836-combined-with-qivs\/","og_site_name":"MabDesign","article_published_time":"2024-03-28T16:59:20+00:00","author":"Laure Delhon","twitter_card":"summary_large_image","twitter_creator":"@MabDesign_fr","twitter_site":"@MabDesign_fr","twitter_misc":{"Written by":"Laure Delhon","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-last-patient-in-phase-2a-clinical-trial-evaluating-ovx836-combined-with-qivs\/#article","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-last-patient-in-phase-2a-clinical-trial-evaluating-ovx836-combined-with-qivs\/"},"author":{"name":"Laure Delhon","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/e7f929f9c28647aff12061d31ac44f39"},"headline":"Osivax Announces Vaccination of Last Patient in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs","datePublished":"2024-03-28T16:59:20+00:00","mainEntityOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-last-patient-in-phase-2a-clinical-trial-evaluating-ovx836-combined-with-qivs\/"},"wordCount":319,"publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-last-patient-in-phase-2a-clinical-trial-evaluating-ovx836-combined-with-qivs\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/09\/OSIVAX-logo.jpg","articleSection":["News","Our members"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-last-patient-in-phase-2a-clinical-trial-evaluating-ovx836-combined-with-qivs\/","url":"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-last-patient-in-phase-2a-clinical-trial-evaluating-ovx836-combined-with-qivs\/","name":"Osivax Announces Vaccination of Last Patient in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs - MabDesign","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-last-patient-in-phase-2a-clinical-trial-evaluating-ovx836-combined-with-qivs\/#primaryimage"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-last-patient-in-phase-2a-clinical-trial-evaluating-ovx836-combined-with-qivs\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/09\/OSIVAX-logo.jpg","datePublished":"2024-03-28T16:59:20+00:00","description":"Osivax,\u00a0a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced\u00a0that all participants have completed their final visit in the Phase 2a clinical trial (NCT05734040) evaluating OVX836, Osivax\u2019 broad-spectrum influenza A vaccine candidate, in combination with Quadrivalent Influenza Vaccines (QIVs).","breadcrumb":{"@id":"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-last-patient-in-phase-2a-clinical-trial-evaluating-ovx836-combined-with-qivs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-last-patient-in-phase-2a-clinical-trial-evaluating-ovx836-combined-with-qivs\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-last-patient-in-phase-2a-clinical-trial-evaluating-ovx836-combined-with-qivs\/#primaryimage","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/09\/OSIVAX-logo.jpg","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/09\/OSIVAX-logo.jpg","width":600,"height":152},{"@type":"BreadcrumbList","@id":"https:\/\/mabdesign.fr\/en\/osivax-announces-vaccination-of-last-patient-in-phase-2a-clinical-trial-evaluating-ovx836-combined-with-qivs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/mabdesign.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Osivax Announces Vaccination of Last Patient in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs"}]},{"@type":"WebSite","@id":"https:\/\/mabdesign.fr\/en\/#website","url":"https:\/\/mabdesign.fr\/en\/","name":"Mabdesign","description":"The Biotherapy Expert","publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mabdesign.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mabdesign.fr\/en\/#organization","name":"Mabdesign","url":"https:\/\/mabdesign.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","width":786,"height":233,"caption":"Mabdesign"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/MabDesign_fr","https:\/\/www.linkedin.com\/company\/mabdesign\/"]},{"@type":"Person","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/e7f929f9c28647aff12061d31ac44f39","name":"Laure Delhon","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/066cd19881c24784247d7cba92fef00a9cef88209b15a463ee495ac0fc2ba664?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/066cd19881c24784247d7cba92fef00a9cef88209b15a463ee495ac0fc2ba664?s=96&d=mm&r=g","caption":"Laure Delhon"},"url":"https:\/\/mabdesign.fr\/en\/author\/laure-delhonmabdesign-fr\/"}]}},"_links":{"self":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/22796","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/comments?post=22796"}],"version-history":[{"count":0,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/22796\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media\/7695"}],"wp:attachment":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media?parent=22796"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/categories?post=22796"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/tags?post=22796"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}